Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity

Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). However, the prevalence of TKI-induced fatigue remains uncertain and little is known about predictors of fatigue and its relationship with physical activity. In this study, 220...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Lando, Blijlevens, Nicole M.A., Drissen, Meggie M.C.M., Bakker, Esmée A., Nuijten, Malou A.H., Janssen, Jeroen J.W.M., Timmers, Silvie, Hopman, Maria T.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252933/
https://www.ncbi.nlm.nih.gov/pubmed/32616528
http://dx.doi.org/10.3324/haematol.2020.247767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252933/
https://www.ncbi.nlm.nih.gov/pubmed/32616528
http://dx.doi.org/10.3324/haematol.2020.247767

Ejemplares similares